Cytotheryx, Inc. Announces Acquisition of Ambys Medicines, Inc. Intellectual Property Assets
Cytotheryx, Inc. announced today it has acquired the intellectual property assets of Ambys Medicines, Inc., which will now become part of our portfolio.
As the premier conference in the liver disease research space, The Liver Meeting brings together leaders for networking, scientific conversations and symposia, and educational workshops. We will be exhibiting at the Liver Meeting Booth C2415 in November and are excited to be contributing to the ongoing excitement around cutting-edge liver disease research.
We will attend the annual JPM week. We’re excited to attend to have meaningful conversations and build relationships with other industry leaders and investors.
Cytotheryx, Inc. announced today it has acquired the intellectual property assets of Ambys Medicines, Inc., which will now become part of our portfolio.
The Cytotheryx team is committed to community volunteering. We’re proud to have spent time volunteering together to keep our city clean and beautiful.
The Cytotheryx team is humbled and honored to have been selected as a 2022 Early Stage BOLD Award Winner at the 10th Annual BOLD Awards!
Currently, the supply of primary human hepatocytes is limited because individual cells are derived from whole livers from organ donors. When these cells become available, they are often unpredictable, inconsistent, and costly, and the number of cells is limited by the size and health of the donated liver. All of these factors can inhibit research and development over time. Cytotheryx’ primary human hepatocytes are more consistent, more readily available, and of a higher quality than alternatives. With our bio-incubators, we are able to develop and replicate dependable, high-quality cells over time, for more consistent sourcing, utilization and results.
Over 4.5 million people in the U.S. have been diagnosed with liver disease, and treatment options for liver disease are limited. While recommended lifestyle changes and therapeutics do exist as treatment options, the only current curative option as liver disease progresses into liver failure is organ transplantation. Hepatocytes have been shown to be valuable in therapeutic applications, such as the treatment of liver failure, through an external liver assist device or through direct cellular therapy. However, a clinically safe and consistent source of those cells does not exist. This unmet need limits the potential of therapeutic applications significantly. With a clinically safe, consistent, and high-quality source of liver cells, additional therapeutics could be developed and advanced for the treatment of liver disease, liver failure and rare diseases. Cytotheryx is prepared to meet that critical need.